Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AHB-137 in Healthy Participants and HBeAg-negative CHB Patients
NCT06115993Phase 2Completed
- Sponsor
- AusperBio
- Start
- Aug 2023
- Primary completion
- Dec 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of AHB-137 in Chronic Hepatitis B (CHB), sponsored by AusperBio. Started Aug 2023; status: completed.
02
Drugs
AHB-137
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06115993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06115993.